A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC

被引：12
|
作者：
Yang, J. - [1 ,2 ]
Fang, J. [3 ]
Shu, Y. [4 ]
Chang, J. [5 ]
Chen, G. [6 ]
He, J. [7 ]
Li, W. [8 ]
Liu, X. [9 ]
Yang, N. [10 ]
Zhou, C. [11 ]
Huang, J. [12 ]
Yang, L. [13 ]
Handzel, A. [14 ]
Frigault, M. [14 ]
Ahmed, G. [15 ]
Egile, C. [15 ]
Morgan, S. [15 ]
Wu, Y. [16 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Beijing Univ, Beijing Canc Hosp, Dept Chest Canc, Beijing, Peoples R China
[4] Nanjing Med Univ, Nanjing, Jiangsu, Peoples R China
[5] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[6] Harbin Med Univ, Canc Hosp, Harbin, Heilongjiang, Peoples R China
[7] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China
[8] Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China
[9] 307 Hosp Chinese Peoples Liberat Army, Dept Pulm Oncol, Beijing, Peoples R China
[10] 307Th Hosp Chinese Peoples Liberat Army, Beijing, Peoples R China
[11] Tongji Univ, Shanghai Pulm Hosp, Med Oncol, Shanghai, Peoples R China
[12] Soochow Univ, Affiliated Hosp 1, Sheng, Jiangsu, Peoples R China
[13] Astrazeneca, Shanghai, Peoples R China
[14] Astrazeneca, Waltham, MA USA
[15] Astrazeneca, Cambridge, England
[16] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
D O I：
10.1016/j.jtho.2017.09.379
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA 09.06
引用
收藏
页码：S1769 / S1769
页数：1
相关论文
共 50 条
  • [1] Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study
    Park, K.
    Zhou, J.
    Kim, D-W.
    Ahmad, A. R.
    Soo, R. A.
    Bruns, R.
    Straub, J.
    Johne, A.
    Scheele, J.
    Yang, J. C-H.
    Wu, Y-L.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [2] TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
    Ahn, M.
    Han, J.
    Sequist, L.
    Cho, B. C.
    Lee, J. S.
    Kim, S.
    Su, W.
    Tsai, C.
    Yang, J. C.
    Yu, H.
    Horn, L.
    Lee, K.
    Haddad, V.
    Frigault, M.
    Ahmed, G.
    Yang, L.
    Ghiorghiu, D.
    Oxnard, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1768 - S1768
  • [3] A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
    Jin-Ji Yang
    Jian Fang
    Yong-Qian Shu
    Jian-Hua Chang
    Gong-Yan Chen
    Jian Xing He
    Wei Li
    Xiao-Qing Liu
    Nong Yang
    Caicun Zhou
    Jian An Huang
    Melanie M. Frigault
    Ryan Hartmaier
    Ghada F. Ahmed
    Coumaran Egile
    Shethah Morgan
    Remy B. Verheijen
    Anders Mellemgaard
    Liu Yang
    Yi-Long Wu
    [J]. Investigational New Drugs, 2021, 39 : 477 - 487
  • [4] SAVANNAH: Phase II Trial of Osimertinib plus Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib
    Ahn, M.
    Cantarini, M.
    Frewer, P.
    Hawkins, G.
    Peters, J.
    Howarth, P.
    Ahmed, G.
    Sahota, T.
    Hartmaier, R.
    Li-Sucholeiki, X.
    Oxnard, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S415 - S416
  • [5] Tepotinib plus gefitinib vs chemotherapy in MET-amplified EGFR-mutant non-small cell lung cancer (NSCLC): Predefined subgroup analysis of a Phase Ib/II study
    Yang, James Chih-Hsin
    Zhou, Jianying
    Kim, Dong-Wan
    Ahmad, Azura Rozila
    Soo, Ross Andrew
    Bruns, Rolf
    Straub, Josef
    Johne, Andreas
    Scheele, Juergen
    Park, Keunchil
    Wu, Yi-Long
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [6] Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
    Wang, Kaiwen
    Du, Robyn
    Roy-Chowdhuri, Sinchita
    Li, Ziping T.
    Hong, Lingzhi
    Vokes, Natalie
    Elamin, Yasir Y.
    Hume, Celyne Bueno
    Skoulidis, Ferdinandos
    Gay, Carl M.
    Blumenschein, George
    Fossella, Frank V.
    Tsao, Anne
    Zhang, Jianjun
    Karachaliou, Niki
    O'Brate, Aurora
    Gann, Claudia-Nanette
    Lewis, Jeff
    Rinsurongkawong, Waree
    Lee, J. Jack
    Gibbons, Don Lynn
    Vaporciyan, Ara A.
    Heymach, John V.
    Altan, Mehmet
    Le, Xiuning
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (08):
  • [7] Tepotinib with an EGFR-tyrosine kinase inhibitor in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Lam, Wei-Sen
    Le, Xiuning
    Eisert, Anna
    Himpe, Ulrike
    De Bondt, Charlotte
    Mazieres, Julien
    Petrini, Iacopo
    Tho, Lye Mun
    Ahmad, Azura
    Chik, Yin Kwan Jeannie
    Lee, Wai Chung Kirsty
    Yang, Tsung-Ying
    Hsia, Te-Chun
    Joshi, Kirti
    Berghoff, Karin
    Vlassak, Soetkin
    Karachaliou, Niki
    Young, Louise
    van der Wekken, Anthonie
    [J]. RESPIROLOGY, 2023, 28 : 14 - 15
  • [8] TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Sequist, Lecia V.
    Lee, Jong Seok
    Han, Ji-Youn
    Su, Wu-Chou
    Yang, James Chih-Hsin
    Yu, Helena
    Ottesen, Lone H.
    Verheijen, Remy B.
    Mellemgaard, Anders
    Wessen, Jonathan
    Oxnard, Geoffrey
    Cho, Byoung Chul
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [9] TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Yu, Helena
    Ahn, Myung-Ju
    Kim, Sang-We
    Cho, Byoung Chul
    Sequist, Lecia
    Orlov, Sergey
    Ottesen, Lone H.
    Verheijen, Remy B.
    Mellemgaard, Anders
    Wessen, Jonathan
    Han, Ji-Youn
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [10] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Ahmad, A. R.
    Tho, L. M.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T-Y.
    Le, X.
    Eisert, A. K.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Lam, W-S.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    Van der Wekken, A. J.
    Hsia, T-C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1584
12345